Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) announced its quarterly earnings results on Tuesday. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($1.68), MarketWatch Earnings reports. Opiant Pharmaceuticals had a net margin of 6.40% and a return on equity of 7.69%. During the same quarter in the prior year, the business earned ($0.66) EPS.
NASDAQ:OPNT traded down $6.57 during mid-day trading on Wednesday, hitting $11.78. 12,074 shares of the company’s stock were exchanged, compared to its average volume of 81,000. The company has a 50 day simple moving average of $22.03 and a 200-day simple moving average of $26.13. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.34. Opiant Pharmaceuticals has a fifty-two week low of $12.00 and a fifty-two week high of $37.71. The firm has a market capitalization of $59.84 million, a P/E ratio of 39.03 and a beta of 0.65.
Several equities research analysts recently commented on the stock. TheStreet downgraded shares of Opiant Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Monday, April 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Opiant Pharmaceuticals in a research report on Wednesday, March 16th.
Opiant Pharmaceuticals Company Profile (Get Rating)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.